Business
Inventiva to Host Analyst and Investor Event on October 8, 2025
Program will include an update on the Company’s lead asset, lanifibranor, ahead of anticipated Phase 3 NATiV3 topline results in the second half of 2026Three renowned international experts and a patient representative will highlight key trends shaping the MASH treatment landscape Daix (France), New York City (New York, United States), September 24, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the developme
About this update from Inventiva Sa
[{"type":"image","alt":"INVENTIVA","displaySize":"","headline":null,"caption":"INVENTIVA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":142,"url":"https://media.zenfs.com/en/globenewswire.com/fef5472de2e52c88120abbdb39dcd123"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IFR.Gz27ItPSlaHquTiPVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/fef5472de2e52c88120abbdb39dcd123","width":300,"height":142}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Program will include an update on the Company’s lead asset, lanifibranor, ahead of anticipated Phase 3 NATiV3 topline results in the second half of 2026","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"Three renowned international experts and a patient representative will highlight key trends shaping the MASH treatment landscape","length":128,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":280,"olType":false},{"type":"text","content":"Daix (France), New York City (New York, United States), September 24, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company will host an analyst and investor event, providing a strategic corporate update ahead of anticipated Phase 3 topline results for lanifibranor, Inventiva’s lead asset for MASH. The event will be held on Wednesday, Oct. 8, 2025, from 11:30am to 2:00pm ET/5:30pm to 8:00pm CET, in New York City and available live via webcast.","length":681,"tagName":"p"},{"type":"text","content":"Agenda topics will include:","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Lanifibranor’s anticipated positioning in a large global market","length":63,"tagName":"p"}]},{"val":[{"type":"text","content":"A deep dive into lanifibranor’s mechanism of action and clinical evidence to date, including key findings from the Phase 2b trial","length":129,"tagName":"p"}]},{"val":[{"type":"text","content":"The design and objectives of the ongoing Phase 3 study as well as a progress update and overview of patient baseline characteristics","length":132,"tagName":"p"}]},{"val":[{"type":"text...